Facebook 20cover 20  202019 20 1
Untitled 20design 20 2

Strados Labs

For clinicians seeking critical respiratory data, Strados non-invasive smart sensors enable remote monitoring and management over the entire episode of care.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded June 2016
  • Employees 6
  • Incorporation Type C-corp
  • Website stradoslabs.com

Company Summary

Strados Labs is a medical technology company focused on improving the way we manage respiratory health. We developed the RESP, the world's first FDA 510(k) cleared lung sound monitor and connected platform that enables doctors to identify abnormal breathing patterns at anytime, anywhere. The technology is often called the "Holter Monitor for the Lungs" and is bringing pulmonary care to patients across the entire care journey.

Team

  • Untitled
    CEO & Founder

    Several years experience in healthcare financial and strategic advisory working with Big Pharma and leading health institutions on projects ranging from physician compensation, value-based payment models, purchase price accounting, due diligence, and strategic forecasting. Mr. Delmonico received an MBA in Healthcare at Temple University where he also started Strados Labs after attending a healthcare hackathon at Jefferson University Health System

  • 7ddc1440 a52b 41f1 95c9 4f4fa9943549
    CIO/COO

    Mr. Powers was CIO of CardioMEMS. Under his leadership at CardioMEMS, Richard and his team designed and developed a secure, cloud-based, remote chronic disease management IoT platform powering the world’s first FDA-approved implantable wireless blood pressure sensor for patients with heart failure that showed a 50% hospitalization reduction rate and was acquired for $455M

  • Default avatar
    Mitchell Glass, MD
    Chief Medical Officer

    Dr. Mitchell Glass is a 30-year veteran of the pharmaceutical industry. His experience is broad, ranging from senior positions in top ten pharmaceutical companies to investment in and management of start-ups and biotechs. He has successful exits and IPOs including AtheroGenix (NASDAQ, 2004) and dozens of successful trials.

  • C6879661 58a1 4d4c af0a e2b82b38dfe0
    Chief Technology Officer

    25+ years experience in developing and commercializing medical device products. He has successfully led teams focused on integrating hardware sensor data with a remote patient monitoring platform for companies like CardioMEMs (acquired by St. Jude Medical of $455M in 2013) and Sarvint Technologies.

Previous Investors